Risk factors for infliximab-induced infusion reactions based on a retrospective study of medical information.

Abstract

Infliximab is indicated for a wide range of diseases, and infusion reactions (IRs) have been reported after infliximab administration in 17.6% of patients in clinical practice. This study aimed to identify the risk factors for IRs before the administration of infliximab based on available patient information. We retrospectively analyzed patients treated with infliximab. Data were compared between patients with and without IRs immediately before initiation of infliximab. Elevated C-reactive protein (CRP) (odds ratio (OR), 2.150; 95% confidence interval (CI), 1.329-3.477; p=0.002) before infliximab administration was a significant risk factor for developing an IR. Patients with elevated CRP levels before therapy initiation may require more careful monitoring after infliximab administration.